Allergan Plc (AGN)

158.25
NYSE : Health Technology
Prev Close 156.34
Day Low/High 156.75 / 158.64
52 Wk Low/High 114.27 / 197.00
Avg Volume 4.78M
Exchange NYSE
Shares Outstanding 328.03M
Market Cap 51.28B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.86%)
Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Aurobindo Pharma Ltd.

Jim Cramer: Markets Expect Too Much from Under Armour, IBM and These Other Names

Jim Cramer: Markets Expect Too Much from Under Armour, IBM and These Other Names

The stocks inexplicably fell even after they delivered good earnings.

Jim's Daily Rundown

Jim discusses the trade tariff deadline extension, Emerson Electric's earnings, last night's interview with Allergan CEO Brent Saunders, Goldman Sachs, 3M and more!

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Alibaba, First American, Coherent: 'Mad Money' Lightning Round

Jim Cramer makes the calls on Alibaba, First American, Coherent, Ionis Pharmacuetical, Skechers USA, Corning, Bank of Internet and more.

Ventas: Cramer's Top Takeaways

Ventas: Cramer's Top Takeaways

Debra Cafaro, chairman and CEO of Ventas, tells Jim Cramer about the company's investment in university research facilities.

Allergan: Cramer's Top Takeaways

Allergan: Cramer's Top Takeaways

Brent Saunders, chairman and CEO of Allergan, talks to Jim Cramer about the company's drug pipeline, and Botox.

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Where's the Real Leadership?: Cramer's 'Mad Money' Recap (Monday 4/30/18)

Love the banks, then hate the banks. Love the industrials? Nope, they're out, too. Jim Cramer says it's ugly, but he would use the weakness in the upside surprises.

Dow, S&P 500 and Nasdaq Decline as M&A Fails to Push Wall Street Higher

Dow, S&P 500 and Nasdaq Decline as M&A Fails to Push Wall Street Higher

Stocks finished lower as Wall Street processes a mega-merger between Sprint and T-Mobile US and as Walmart says it will sell its supermarket business in the U.K.

Allergan Is Still In a Downtrend as We Wait for a Bottom to Form

Allergan Is Still In a Downtrend as We Wait for a Bottom to Form

Allergan's bottom is going to take more time.

Allergan First Quarter Earnings

The market is looking past the positive results as the commentary surrounding the breakup overshadowed the earnings.

Jim's Daily Rundown

Jim discusses Allergan, Apple, broken stocks vs. broken companies and more!

Video: Jim Cramer on T-Mobile, Sprint, AT&T, Centene and Allergan

Video: Jim Cramer on T-Mobile, Sprint, AT&T, Centene and Allergan

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Monday's trending stocks from the floor of the New York Stock Exchange.

Selling Some Lilly; Adding to PepsiCo

We will make a small sale in LLY and use the proceeds and opportunity to scoop up more PEP.

Sprint, T-Mobile, Walmart and McDonald's - 5 Things You Must Know

Sprint, T-Mobile, Walmart and McDonald's - 5 Things You Must Know

U.S. stock futures are rising Monday, as Wall Street processes a mega-merger between Sprint and T-Mobile and as Walmart says it will sell its supermarket business in the U.K.

Fighting Crosswinds: Cramer's 'Mad Money' Recap (Friday 4/27/18)

Fighting Crosswinds: Cramer's 'Mad Money' Recap (Friday 4/27/18)

Jim Cramer says foolish traders believe a trade war will trigger a recession, but they're wrong. Fight the crosswinds with a game plan for next week.

Weekly Roundup

Markets end flat for week as strong earnings fail to excite investors.

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

Allergan Unveils Positive Data for New Migraine Drug

Allergan Unveils Positive Data for New Migraine Drug

The Dublin drugmaker announced data from Achieve II, a clinical trial evaluating potential migraine treatment drug ubrogepant.

Following Up on 3M

We believe that today's heavy selloff is an overreaction.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Weekly Roundup

Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.

Some Biotech Stocks to Add Exposure To

Some Biotech Stocks to Add Exposure To

Secondary offerings create buying opportunities.

Jim's Daily Rundown

Jim discusses earnings from Nucor and Danaher, recent headlines about Apple, Amazon, Allergan, and more!

Revance Therapeutics Stock Looks Ready for New Gains

Revance Therapeutics Stock Looks Ready for New Gains

I don't understand the fundamentals but I find the chart interesting.

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Revance Therapeutics: Cramer's Top Takeaways

Revance Therapeutics: Cramer's Top Takeaways

Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Weekly Roundup

The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

TheStreet Quant Rating: C (Hold)